Valuation: Astellas Pharma Inc.

Market Cap 4,484B 28.3B 25.22B 23.12B 21.01B 39.51B 2,674B 40.41B 276B 111B 1,415B 106B 104B P/E 2027 *
11.4x
P/E 2028 * 12.3x
Enterprise Value 4,424B 27.92B 24.88B 22.82B 20.74B 38.98B 2,639B 39.87B 273B 109B 1,397B 105B 103B EV / Sales 2027 *
1.86x
EV / Sales 2028 * 1.81x
Free-Float
98.92%
Yield 2027 *
3.21%
Yield 2028 * 3.32%
1 day+7.20%
1 week+6.67%
Current month+4.26%
1 month+19.93%
3 months+24.15%
6 months+16.44%
Current year+28.07%
1 week 2,468.5
Extreme 2468.5
2,753
1 month 2,216
Extreme 2216
2,753
Current year 2,041
Extreme 2041
2,753
1 year 1,688
Extreme 1688
2,753
3 years 1,243.5
Extreme 1243.5
2,753
5 years 1,243.5
Extreme 1243.5
2,753
10 years 1,243.5
Extreme 1243.5
2,753
Manager TitleAgeSince
Chief Executive Officer 64 2023-02-09
Director of Finance/CFO 55 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 64 2019-05-31
Director/Board Member 59 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+6.88%+6.67%+57.91%+50.21% 29.07B
+0.61%+10.07%+56.36%+149.73% 1,255B
+3.81%+1.95%+47.88%+82.58% 641B
+3.09%+3.09%+36.56%+108.48% 505B
+1.25%-0.73%+49.96%+66.87% 381B
+3.93%+6.69%+79.30%+45.44% 357B
+2.10%+3.90%+32.30%+61.10% 303B
+1.92%+9.87%+11.94%+36.55% 286B
+3.73%+5.90%+61.27%+77.31% 249B
+4.19%+9.60%+41.85%+113.85% 208B
Average +3.18%+4.77%+47.53%+79.21% 421.43B
Weighted average by Cap. +2.34%+5.70%+48.90%+97.46%

Financials

2027 *2028 *
Net sales 2,375B 14.99B 13.35B 12.25B 11.13B 20.92B 1,416B 21.4B 146B 58.67B 750B 56.25B 55.04B 2,213B 13.97B 12.45B 11.42B 10.37B 19.5B 1,320B 19.95B 136B 54.69B 699B 52.43B 51.31B
Net income 378B 2.38B 2.12B 1.95B 1.77B 3.33B 225B 3.4B 23.28B 9.33B 119B 8.95B 8.76B 346B 2.18B 1.95B 1.78B 1.62B 3.05B 206B 3.12B 21.33B 8.55B 109B 8.2B 8.02B
Net Debt -59.3B -374M -333M -306M -278M -522M -35.37B -534M -3.66B -1.47B -18.72B -1.4B -1.37B -481B -3.03B -2.7B -2.48B -2.25B -4.23B -287B -4.33B -29.63B -11.88B -152B -11.39B -11.14B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-11-04 JP¥2,673.00 +6.90% 5,607,300
26-11-04 JP¥2,500.50 -2.67% 8,118,400
26-11-02 JP¥2,569.00 -0.08% 4,685,400
26-10-30 JP¥2,571.00 +2.31% 6,563,100
26-10-29 JP¥2,513.00 +0.48% 10,821,400
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,500.50JPY
Average target price
2,536.43JPY
Spread / Average Target
+1.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.
  1. Stock Market
  2. Stocks
  3. 4503 Stock